# Pulp–Dentin Regeneration via Cell Homing: Current Evidence and Perspectives on Cell-Free Regenerative Endodontic Therapy

**Authors:** Michele Beco, Francesca Di Pasquale, Chiara Valenti, Paolo Betti, Gian Luca Mascolo, Lorella Marinucci, Stefano Eramo, Stefano Pagano

PMC · DOI: 10.3390/medicina62020375 · Medicina · 2026-02-13

## TL;DR

This paper reviews recent studies on cell-free regenerative endodontic therapy, which uses the body's own stem cells to regenerate pulp and dentin, offering a potential alternative to traditional root canal treatments.

## Contribution

The study provides an updated analysis of recent human studies on CF-RET, highlighting its biological potential and the need for standardized clinical protocols.

## Key findings

- In vitro studies show growth factors and biomimetic scaffolds enhance stem cell viability and odontogenic differentiation.
- In vivo studies on immature teeth show positive outcomes like root development and canal diameter reduction.
- Current evidence is limited by heterogeneity and lack of standardized protocols.

## Abstract

Background and Objectives: The regeneration of the pulp–dentin complex represents an alternative to conventional root canal treatment, aiming to preserve tooth biology and function. Cell-free regenerative endodontic therapy (CF-RET) exploits endogenous stem cells from the periapical region without ex vivo cell manipulation. Despite growing interest, the biological mechanisms, clinical indications, and predictability of CF-RET remain not clearly defined. This structured narrative review aimed to update a previous review by analyzing recent human studies on CF-RET. Materials and Methods: This review was conducted using the PRISMA 2020 guidelines to guide transparent reporting of the literature search and study selection process and was registered in PROSPERO (CRD420251075131). In vitro and in vivo human studies published between January 2017 and December 2024 investigating CF-RET were included, while studies involving cell transplantation, non-human models, case reports, and reviews were excluded. Study selection, data extraction, and quality assessment using the QuADS tool were performed, and the evidence was synthesized using a qualitative narrative approach. Results: Sixty-four studies were included. In vitro studies reported favorable effects of growth factors, exosomes, and biomimetic scaffolds on stem cell viability, migration, proliferation, odontogenic differentiation, and angiogenesis, while neurogenic differentiation was less consistently investigated. Scaffold composition, microstructure, and rheological properties were also considered. In vivo studies mainly focused on immature teeth with incomplete root development and demonstrated positive clinical and radiographic outcomes, including root development and canal diameter reduction. Conclusions: The current evidence supports the biological potential of CF-RET as a regenerative approach; however, substantial heterogeneity, the limited number of clinical studies and the absence of standardized protocols preclude definitive conclusions, highlighting the need for further well-designed translational and clinical investigations considering clinical applicability.

## Full-text entities

- **Genes:** DMP1 (dentin matrix acidic phosphoprotein 1) [NCBI Gene 1758] {aka ARHP, ARHR, DMP-1}, KLF5 (KLF transcription factor 5) [NCBI Gene 688] {aka BTEB2, CKLF, IKLF}, MIR584 (microRNA 584) [NCBI Gene 693169] {aka MIRN584, hsa-mir-584}, MSX2 (msh homeobox 2) [NCBI Gene 4488] {aka CRS2, FPP, HOX8, MSH, PFM, PFM1}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], DSPP (dentin sialophosphoprotein) [NCBI Gene 1834] {aka DFNA39, DGI1, DMP3, DPP, DSP}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, CTCF (CCCTC-binding factor) [NCBI Gene 10664] {aka CFAP108, FAP108, MRD21}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, KDM4D (lysine demethylase 4D) [NCBI Gene 55693] {aka JMJD2D}, ITGAV (integrin subunit alpha V) [NCBI Gene 3685] {aka CD51, IDNDC, MSK8, VNRA, VTNR}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PLAUR (plasminogen activator, urokinase receptor) [NCBI Gene 5329] {aka CD87, U-PAR, UPAR, URKR}, DLX5 (distal-less homeobox 5) [NCBI Gene 1749] {aka SHFM1, SHFM1D}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, BGN (biglycan) [NCBI Gene 633] {aka DSPG1, MRLS, PG-S1, PGI, SEMDX, SLRR1A}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, PRAP1 (proline rich acidic protein 1) [NCBI Gene 118471] {aka PRO1195, UPA}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, SP7 (Sp7 transcription factor) [NCBI Gene 121340] {aka OI11, OI12, OSX, osterix}, SCAP (SREBF chaperone) [NCBI Gene 22937], WNT7B (Wnt family member 7B) [NCBI Gene 7477], CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, DSP (desmoplakin) [NCBI Gene 1832] {aka DCWHKTA, DP}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, RPS5 (ribosomal protein S5) [NCBI Gene 6193] {aka S5, uS7}, ATHS (atherosclerosis susceptibility (lipoprotein associated)) [NCBI Gene 470] {aka ALP}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, IBSP (integrin binding sialoprotein) [NCBI Gene 3381] {aka BNSP, BSP, BSP II, BSP-II, SP-II}, ITGA5 (integrin subunit alpha 5) [NCBI Gene 3678] {aka CD49e, FNRA, VLA-5, VLA5A}, MIR224 (microRNA 224) [NCBI Gene 407009] {aka MIRN224, miRNA224}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PRMT6 (protein arginine methyltransferase 6) [NCBI Gene 55170] {aka HRMT1L6}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, ANG (angiogenin) [NCBI Gene 283] {aka ALS9, HEL168, RAA1, RNASE4, RNASE5}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}
- **Diseases:** pulpitis (MESH:D011671), pulp (MESH:D003788), necrotic (MESH:D009336), crown discoloration (MESH:D014075), Dental caries (MESH:D003731), cytotoxicity (MESH:D064420), APC (MESH:D011125), infected (MESH:D007239), pulpal disease (MESH:D003784), periapical lesion (MESH:D010483), Bleeding (MESH:D006470), periradicular lesion (MESH:D009059), pain (MESH:D010146), pulp necrosis (MESH:D003790), inflammation of (MESH:D007249), dental trauma (MESH:D014947), apical periodontitis (MESH:D010485), RCT (MESH:D011843), swelling (MESH:D004487), DM (MESH:D009223)
- **Chemicals:** minocycline (MESH:D008911), PLA (MESH:C033616), SU5416 (MESH:C116890), i (MESH:D007455), TCP (MESH:C049563), Alamar Blue (MESH:C005843), Biodentine (MESH:C506393), LY294002 (MESH:C085911), DAPI (MESH:C007293), calcium (MESH:D002118), Alizarin Red S (MESH:C004468), PBS (MESH:D007854), KCl (MESH:D011189), H (MESH:D006859), Simvastatin (MESH:D019821), hematoxylin (MESH:D006416), CF (MESH:D002142), Dentonin (-), Alizarin Red (MESH:C010078), Melatonin (MESH:D008550), NaOCl (MESH:D012973), O-cresol phthaleincomplexone (MESH:C017845), Ca(OH)2 (MESH:D002126), dexamethasone (MESH:D003907), MTT (MESH:C070243), Dex (MESH:D003915), TB (MESH:D013725), CPC (MESH:C015101), polyethylene (MESH:D020959), PF573228 (MESH:C521108), Chlorhexidine (MESH:D002710), Chitosan (MESH:D048271), CCK- (MESH:D002766), Kappa-carrageenan (MESH:D002351), MTA (MESH:C086631), saline (MESH:D012965), ciprofloxacin (MESH:D002939), SB203580 (MESH:C093642), calcium-silicate (MESH:C031293), metronidazole (MESH:D008795), F12 (MESH:C007782), EDTA (MESH:D004492)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Enterococcus faecalis (species) [taxon 1351], Canis lupus familiaris (dog, subspecies) [taxon 9615]
- **Cell lines:** CH — Manduca sexta (Tobacco hawkmoth), Spontaneously immortalized cell line (CVCL_Z389), Ca — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z839), DPSC — Homo sapiens (Human), Somatic stem cell (CVCL_AV90), CH-SV — Mus musculus (Mouse), Transformed cell line (CVCL_E938)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942805/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12942805/full.md

## References

86 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942805/full.md

---
Source: https://tomesphere.com/paper/PMC12942805